The operating profit before interest, depreciation, exceptional items and taxation moved up by just 3.9% to Rs 25.6 crore from Rs 24.6 crore. The company sold its Ankleshwar plant and shown a profit of Rs 2.87 crore as exceptional income in the third quarter ended August 2004, which has increased its net profit. However, the companys gross sales during the third quarter ended August 2004, declined marginally to Rs 158.8 crore from Rs 158.95 crore. The net sales, after excise duty and sales tax, declined to Rs 134.2 crore from Rs 134.88 crore in the similar period of last year. The sales of pharmaceuticals segment declined to Rs 121.13 crore from Rs 124.7 crore. However, its animal health division improved its sales to Rs 14.67 crore from Rs 13.35 crore.
Pfizers income from services increased to Rs 3.88 crore from Rs 3.24 crore. The companys other income also declined by 4.9% to Rs 8.6 crore from Rs 9.04 crore. Its other income includes service income of Rs 5.47 crore as compared to Rs 6.4 crore. The companys gross sales for the nine months period increased by 14.8% to Rs 462.8 crore from Rs 403.1 crore in the corresponding period of last year. The net sales also moved up by 14% to Rs 390.88 crore.